Reirradiation of lower gastrointestinal Cancer: A survey of ongoing trials by the Reirradiation Collaborative group (ReCOG) Authors: Camilla Kronborg, Ane Appelt, Pim Burger, Kyle Cuneo, Aileen Duffton, Maria Gambacorta, Marianne G. Guren, Christopher Hallemeier, Allen Mo, Rebecca Muirhead, Donna H. Murrell, Dawn Owen, Heike Peulen, Heidi S. Rønde, Karen-Lise G. Spindler, Jennifer Tan, Abraham J. Wu, Kilian E. Salerno Published: 2026 ABSTRACT Background and purposePelvic reirradiation is increasingly used for locally recurrent rectal and anal cancers, either to facilitate salvage surgery or to improve local control when surgery is not feasible. However, prospective evidence remains limited, and studies often lack sufficient methodological detail to support interpretation across trials. We aimed to identify ongoing lower gastrointestinal reirradiation trials and describe characteristics, heterogeneity, and evidence gaps.Materials and methodsThe Reirradiation Collaborative Group lower gastrointestinal working group performed a registry-based search for prospective pelvic reirradiation studies in rectal and anal cancer. Eligible studies were prospective, observational or interventional trials involving reirradiation for lower gastrointestinal cancers. Principal investigators were invited to complete a structured 40-item questionnaire covering trial design, reirradiation definition, clinical intent, endpoints, use of patient-reported outcomes (PROs), radiotherapy technique, target, and cumulative dose evaluation.ResultsOf 27 identified studies, 21 were eligible and investigators from 9 trials completed the questionnaire. Most trials used type 1 reirradiation (overlap of irradiated volumes) according to the ESTRO/EORTC framework, but substantial heterogeneity was observed in dose-fractionation, modality, target volume margins, organs of interest, dose objectives, and cumulative dose methodology. Toxicity was assessed with CTCAE, and most studies incorporated PROs, although instruments and timepoints varied. Based on these findings, we propose 12 pragmatic recommendations for lower gastrointestinal reirradiation trials.ConclusionProspective lower gastrointestinal reirradiation trials show methodological heterogeneity. Standardization of definitions, dosimetric data capture, and toxicity and PRO reporting may improve interpretability, comparability, and future evidence synthesis. Introduction There is growing interest in and use of reirradiation in the treatment of recurrent lower gastrointestinal (GI) malignancies. Locally recurrent rectal cancer (LRRC) occurs in approximately 5–12% [1], [2] of patients despite modern primary multimodality management. For anal cancers, pelvic incomplete response or recurrences occur in 15–33% of patients [3]. Reirradiation for local recurrences has seen considerable interest and clinical use in rectal cancer, where it plays an important role as an adjuvant to or alternative to salvage surgery [2], but it has been less explored for anal cancer. Local pelvic recurrences are often adjacent to or involve critical pelvic organs such as bowel and bladder. In many patients, prior pelvic radiotherapy (RT) has already delivered doses near conventional tolerance levels [4], [5]. Consequently, even though pelvic reirradiation may improve resectability and local control for recurrent disease, there are concerns about toxicity from cumulative doses. Evidence to support the use of pelvic reirradiation in LRRC or anal cancer is heterogeneous and has consisted largely of retrospective series and small single-centre cohorts, often combining a broad range of fractionation schedules and techniques [6], [7]. Several studies suggest that reirradiation for LRRC can increase radical resection rates and improve locoregional control [4], [5]. Both hyperfractionated chemoradiation with total doses of 30–45 Gy and hypofractionated or stereotactic body radiotherapy (SBRT) regimens have been used [5], [8], [9] for different indications. More recently, proton or carbon-ion therapy have been used to reduce cumulative dose to normal tissue [10], [11], [12], [13]. In parallel, the broader reirradiation community has recognised the need for standardised terminology and reporting. This has led to reports such as the European Society for Radiotherapy and Oncology/ European Organisation for Research and treatment of Cancer (ESTRO/EORTC) consensus on reirradiation definitions, reporting and decision making and the ESTRO recommendations for use, planning and delivery of reirradiation [14], [15]. International surveys have reported substantial variation in reirradiation dose constraints and planning approaches, underlining the absence of robust, site-specific guidance and high-level evidence [14], [15], [16], [17], [18], [19]. There are several new and ongoing prospective trials that will provide guidance on these matters; however, the results will not be ready within the next few years. The Reirradiation Collaborative Group (ReCOG) [20] lower GI working group identified this issue, but also that capturing and sharing practical insights from ongoing studies could contribute to disease-specific guidance while awaiting results from these prospective trials, as well as inform future studies. The aim of this work was consequently to systematically identify ongoing prospective pelvic reirradiation studies in rectal and anal cancer, and describe key trial principles, treatment guidance, and evidence gaps. Methods and materials Study design and search strategy ReCOG is an international multidisciplinary group supporting clinical practice, research, and policy in reirradiation. The ReCOG Lower GI working group consists of 11 international experts on pelvic reirradiation, 5 radiation oncologists, 3 medical physicists, 2 clinical oncologists, and one radiation therapist. Clinical trial registries were used to search for eligible prospective reirradiation trials for recurrent rectal and anal cancer, and principal investigators (PIs) for the studies identified were contacted and asked to complete a detailed study questionnaire. An initial search on the clinical trials webpage (clinicaltrials.gov) was performed on July 11, 2024. A final updated search was performed on January 27, 2025. In addition, the National Institute for Health and Care Research/ National Health Service (NIHR/NHS) and International Standard Randomised Controlled Trial Number (ISRCTN) webpages were searched on the same dates. The search terms can be found in supplementary appendix 1. Inclusion and exclusion criteria We included studies on reirradiation that were categorized as “recruiting”, “not yet recruiting”, “active, not recruiting”, or “completed”. Only prospective studies, either observational or interventional, were considered. Studies that had published final results as well as retrospective and in-silico studies were excluded. Questionnaire development and content A dedicated 40-item questionnaire was developed by the working group to capture protocol-level details not readily available from registry entries. The questionnaire included the following domains: study identification and status, definition of reirradiation and clinical intent, endpoints and eligibility criteria, adverse effects and patient reported outcome (PRO) assessment, treatment details (including dose and fractionation, modality, patient preparation and imaging), target and organs of interest (OOI) delineation and cumulative dose evaluation. The full questionnaire is available in the supplementary appendix 2. Piloting The questionnaire underwent qualitative assessment of content validity by five members of the ReCOG Lower GI working group following discussion within the full working group. Feedback resulted in refinement of terminology and clarification of cumulative-dose questions. Because the survey was designed as an exploratory data-collection tool for protocol-level information, formal psychometric validation was not undertaken. Distribution An email was sent to all PIs of the identified prospective studies describing the survey and including an invitation to complete one questionnaire per eligible trial. The questionnaire was then distributed electronically to PIs after they accepted participation in the survey. Invitations were sent to PIs May 8, 2025, with a follow up reminder on May 26, 2025. Email addresses were found on the clinical trials entry. In June/July 2025, additional emails were sent to alternative emails, for example listed co-PIs or institutions. On July 3, 2025 reminders were sent to the PIs who agreed to participate but not yet completed the questionnaire. A final reminder was sent October 23, 2025. Recommendations Following completion of the survey analysis, pragmatic recommendations for future lower gastrointestinal reirradiation trials were developed through iterative discussions within the eleven-member ReCOG Lower GI working group. No formal Delphi process, predefined voting threshold, or consensus methodology was used. Statistics Data from clinical trial registries and completed questionnaires were summarized using descriptive statistics at the trial level. Categorical variables were reported as counts and proportions (n/N, %), where the denominator corresponded to the number of studies providing evaluable responses to the relevant question. Partial questionnaires were accepted, and missing responses were treated as missing data. Results The study search identified 26 potentially eligible studies. The PelvEx II trial was subsequently identified by reference from the ReCOG Lower GI working group, adding up to 27 in total. After further review, 6 studies were excluded as they did not include reirradiation, leaving 21 studies eligible for full data collection. Study characteristics Email invitations were sent to 21 PIs. Six e-mails returned with “unable to deliver” and a further three of those invited did not respond to any emails. Of the remaining 12, one responded that the study was not going to be initiated, and two responded positively to e-mails but did not complete the questionnaire. PIs from nine distinct prospective reirradiation studies completed the questionnaire. A table with characteristics from all 21 studies, retrieved from entries on clinicaltrials.gov can be seen in supplementary table 1. A comparison of key study characteristics between survey responders and non-responders is provided in Supplementary Table 2. Although the numbers were small, the groups differed particularly in trial phase and geographical distribution. The included studies and dates of questionnaire completion were RETRY (NCT05984576, 6/2/2025), ReRad III/DACG V (NCT05055635, 10/27/2025), IMPARC (NCT04827732, 7/3/2025), ReRad II (NCT04695782, 10/27/2025), PelvEx II (NCT04389086, 6/2/2025), ReRad I (NCT 05816980, 10/27/2025), NCT03297710, 10/29/2025, NCT02199236, 6/2/2025 and NCT01493206, 11/5/2025. NCT number, location, acronym, tumour type (rectal/anal), interventions, and primary outcomes measure as retrieved from clinical trials are summarized in Table 1.Table 1Description of included reirradiation studies, as described on clinicaltrials.gov.NCT NumberLocationsAcronymRectal/AnalInterventionsPrimary Outcome MeasuresRadiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study05984576Trial 3ItalyRETRYRectalRADIATION: Reirradiation3-year LCRe-irradiation for Pelvic Recurrences in Rectal Cancer Patients05816980Trial 7Denmark, NorwayRe-RAD-IRectalRADIATION: Hyperfractionated external beam reiradiationR0 resectionPencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated with Radiotherapy (DACG 5)05055635 Trial 5DenmarkReRad IIIAnalRADIATION: Pencil beam proton therapy1-year LCHypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer04827732 Trial 4United StatesIMPARCRectalRADIATION: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton TherapyDEVICE: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy MachineMTD/DLTPencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy04695782 Trial 6DenmarkReRad IIRectalRADIATION: Pencil beam proton radiotherapy1-year LCInduction Chemotherapy for Locally Recurrent Rectal Cancer04389086 Trial 1Belgium, Netherlands, Norway, Portugal, SwedenPelvEx IIRectalRADIATION: ChemoradiotherapyDRUG: Combination drugPROCEDURE: Surgery locally recurrent rectal cancerR0 resectionTAS-102 and Radiation Therapy in Treating Patients with Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery03297710Trial 8United States–RectalRADIATION: Radiation TherapyDRUG: Trifluridine/Tipiracil Hydrochloride Combination Agent (TAS-102)OTHER: QoL assessmentsMTD/DLTDose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy with Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management02199236 Trial 2United States–Rectal or AnalRADIATION: endorectal brachytherapyDRUG: concurrent capecitabine or 5-FUBEHAVIORAL: QuestionnairesMTD/DLTA Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer01493206 Trial 9Australia–RectalRADIATION:3-year LRC, PFS, and OSAbbreviations: DLT; dose limiting toxicity 5-FU: 5-fluorouracil, IORT: intraoperative radiotherapy; LC: local control, LRC: locoregional control, MTD: maximum tolerated dose, OS: overall survival, PFS: progression-free survival, QoL: quality of life, R0: margin negative resection. Table 1Description of included reirradiation studies, as described on clinicaltrials.gov.NCT NumberLocationsAcronymRectal/AnalInterventionsPrimary Outcome MeasuresRadiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study05984576Trial 3ItalyRETRYRectalRADIATION: Reirradiation3-year LCRe-irradiation for Pelvic Recurrences in Rectal Cancer Patients05816980Trial 7Denmark, NorwayRe-RAD-IRectalRADIATION: Hyperfractionated external beam reiradiationR0 resectionPencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated with Radiotherapy (DACG 5)05055635 Trial 5DenmarkReRad IIIAnalRADIATION: Pencil beam proton therapy1-year LCHypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer04827732 Trial 4United StatesIMPARCRectalRADIATION: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton TherapyDEVICE: MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy MachineMTD/DLTPencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy04695782 Trial 6DenmarkReRad IIRectalRADIATION: Pencil beam proton radiotherapy1-year LCInduction Chemotherapy for Locally Recurrent Rectal Cancer04389086 Trial 1Belgium, Netherlands, Norway, Portugal, SwedenPelvEx IIRectalRADIATION: ChemoradiotherapyDRUG: Combination drugPROCEDURE: Surgery locally recurrent rectal cancerR0 resectionTAS-102 and Radiation Therapy in Treating Patients with Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery03297710Trial 8United States–RectalRADIATION: Radiation TherapyDRUG: Trifluridine/Tipiracil Hydrochloride Combination Agent (TAS-102)OTHER: QoL assessmentsMTD/DLTDose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy with Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management02199236 Trial 2United States–Rectal or AnalRADIATION: endorectal brachytherapyDRUG: concurrent capecitabine or 5-FUBEHAVIORAL: QuestionnairesMTD/DLTA Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer01493206 Trial 9Australia–RectalRADIATION:3-year LRC, PFS, and OSAbbreviations: DLT; dose limiting toxicity 5-FU: 5-fluorouracil, IORT: intraoperative radiotherapy; LC: local control, LRC: locoregional control, MTD: maximum tolerated dose, OS: overall survival, PFS: progression-free survival, QoL: quality of life, R0: margin negative resection. Description of included reirradiation studies, as described on clinicaltrials.gov. Abbreviations: DLT; dose limiting toxicity 5-FU: 5-fluorouracil, IORT: intraoperative radiotherapy; LC: local control, LRC: locoregional control, MTD: maximum tolerated dose, OS: overall survival, PFS: progression-free survival, QoL: quality of life, R0: margin negative resection. Seven trials included patients with LRRC, one trial included both anal and rectal cancer, and one anal cancer only. Three studies were based in the US, two in Denmark, one in Italy, one in Australia, and two included multiple sites, but led by The Netherlands and Denmark. At the time of questionnaire completion, four studies were listed as recruiting, three as completed, and two as closed early. Definition and intent of reirradiation and chemotherapy Participants were asked to define type of reirradiation as done in Andratschke et al. [14]. According to this classification, type 1 reirradiation has overlap with prior radiation treated volumes, with or without concern for toxicity, and type 2 reirradiation does not have overlap, but has concern for toxicity of cumulative doses. Additional (non-reirradiation) scenarios include repeat organ irradiation and repeat irradiation. Seven trials defined reirradiation as type 1, one of these included both type 1 and patients with no prior RT. One trial (RETRY) considered a broader range with both type 1, type 2, repeat organ irradiation, and repeat irradiation, and one trial (IMPARC) focused on repeat organ irradiation (Table 2).Table 2Reirradiation characteristics on included trials.StudyType of ReirradiationModalityIntent of ReirradiationReirradiation DoseTrial 1:04389086PelvEx II1•Photon, IMRT/VMAT•IORTPreoperative30 Gy in 15 fractionsTrial 2:02199236-1•BrachytherapyDefinitive15 Gy in 5 Gy fractions - 21Gy in 7 Gy fractionsTrial 305,984,576RETRY1, 2, repeat organ irradiation, repeat irradiation•Photon, IMRT/VMAT•Proton, IMPT•CIRT•MRIgRTPreoperativeDefinitivePhoton/protons 40–50 Gy in 20–25 fractionsSBRT 35–40 Gy in 5 fractionsCIRT 40–60 Gy(RBE) in 3–4.8 Gy(RBE)/fractionsTrial 4:04827732IMPARCRepeat organ irradiation•Proton, IMPTPreoperativeDefinitive30–40 Gy in 5 fractionsTrial 5:05055635ReRad III1•Proton, IMPTPreoperativeDefinitivePreoperative: 55 Gy in 44 fractionsDefinitive: 57.5–65 Gy in 46–52 fractionsTrial 6:04695782ReRad II1•Proton, IMPTPreoperativeDefinitivePreoperative: 55 Gy in 44 fractionsDefinitive: 57.5–65 Gy in 46–52 fractionsTrial 7:05816980Re-Rad ITrial 71•Photon IMRT/VMATPreoperative40.8 Gy in 34 fractionsTrial 8:03297710-1 (or no prior irradiation)•Photon, 3D/IMRT/VMATDefinitive30 Gy in 10 fractionsTrial 9:01493206-1•Photon, IMRT/VMAT•IORTPreoperative39.6 in 22 fractions (non reirradiation 50.4 Gy)IORT 10 GyAbbreviations: CIRT: carbon ion radiotherapy, Fractions: fractions, Gy: Gray, IMPT: intensity modulated proton therapy, IMRT: intensity modulated radiotherapy; IORT: intraoperative radiotherapy, MRIgRT: magnetic resonance imaging guided radiotherapy, RBE: relative biological effectiveness, VMAT: volumetric modulated arc therapy. Table 2Reirradiation characteristics on included trials.StudyType of ReirradiationModalityIntent of ReirradiationReirradiation DoseTrial 1:04389086PelvEx II1•Photon, IMRT/VMAT•IORTPreoperative30 Gy in 15 fractionsTrial 2:02199236-1•BrachytherapyDefinitive15 Gy in 5 Gy fractions - 21Gy in 7 Gy fractionsTrial 305,984,576RETRY1, 2, repeat organ irradiation, repeat irradiation•Photon, IMRT/VMAT•Proton, IMPT•CIRT•MRIgRTPreoperativeDefinitivePhoton/protons 40–50 Gy in 20–25 fractionsSBRT 35–40 Gy in 5 fractionsCIRT 40–60 Gy(RBE) in 3–4.8 Gy(RBE)/fractionsTrial 4:04827732IMPARCRepeat organ irradiation•Proton, IMPTPreoperativeDefinitive30–40 Gy in 5 fractionsTrial 5:05055635ReRad III1•Proton, IMPTPreoperativeDefinitivePreoperative: 55 Gy in 44 fractionsDefinitive: 57.5–65 Gy in 46–52 fractionsTrial 6:04695782ReRad II1•Proton, IMPTPreoperativeDefinitivePreoperative: 55 Gy in 44 fractionsDefinitive: 57.5–65 Gy in 46–52 fractionsTrial 7:05816980Re-Rad ITrial 71•Photon IMRT/VMATPreoperative40.8 Gy in 34 fractionsTrial 8:03297710-1 (or no prior irradiation)•Photon, 3D/IMRT/VMATDefinitive30 Gy in 10 fractionsTrial 9:01493206-1•Photon, IMRT/VMAT•IORTPreoperative39.6 in 22 fractions (non reirradiation 50.4 Gy)IORT 10 GyAbbreviations: CIRT: carbon ion radiotherapy, Fractions: fractions, Gy: Gray, IMPT: intensity modulated proton therapy, IMRT: intensity modulated radiotherapy; IORT: intraoperative radiotherapy, MRIgRT: magnetic resonance imaging guided radiotherapy, RBE: relative biological effectiveness, VMAT: volumetric modulated arc therapy. Reirradiation characteristics on included trials. •Photon, IMRT/VMAT Photon, IMRT/VMAT •IORT IORT •Brachytherapy Brachytherapy •Photon, IMRT/VMAT Photon, IMRT/VMAT •Proton, IMPT Proton, IMPT •CIRT CIRT •MRIgRT MRIgRT •Proton, IMPT Proton, IMPT •Proton, IMPT Proton, IMPT •Proton, IMPT Proton, IMPT •Photon IMRT/VMAT Photon IMRT/VMAT •Photon, 3D/IMRT/VMAT Photon, 3D/IMRT/VMAT •Photon, IMRT/VMAT Photon, IMRT/VMAT •IORT IORT Abbreviations: CIRT: carbon ion radiotherapy, Fractions: fractions, Gy: Gray, IMPT: intensity modulated proton therapy, IMRT: intensity modulated radiotherapy; IORT: intraoperative radiotherapy, MRIgRT: magnetic resonance imaging guided radiotherapy, RBE: relative biological effectiveness, VMAT: volumetric modulated arc therapy. The treatment intent was distributed as follows: preoperative only (n = 3), definitive only (n = 2), and both preoperative and definitive (n = 4). Use of concurrent sensitizing systemic therapy was common; as eight trials used capecitabine or 5-fluorouracil, one trial for anal cancer used cisplatin, and one trial had TAS-102 as the experimental drug. Induction therapy was used in one trial (PelvEx II), where patients were randomised to induction chemotherapy or not, and used on individual basis in two trials; whereas consolidation therapy was used in one trial (RETRY) and on individual basis in another. In the five studies that included resection as part of the protocol, surgery was typically scheduled 8 weeks after reirradiation. For one of these, patients also underwent surgery after 3–4 cycles of consolidation chemotherapy. One study planned surgery 10–14 weeks after reirradiation generally with intraoperative radiotherapy (IORT), and one immediately after reirradiation (external beam radiotherapy - EBRT) followed by IORT in the same surgical procedure. Eligibility criteria Consistent eligibility criteria across studies included: age ≥ 18 years; histologically, cytologically or clinically confirmed locally recurrent rectal or anal carcinoma; and ECOG performance status 0–2 (n = 6) or 0–1 (n = 2), with one study not specifying. Where specifically stated, the minimum required life expectancy ranged from 12 weeks to 24 months. Most studies defined presence of unresectable metastatic disease as an exclusion criterion, while one study specifically allowed this. Inclusion/exclusion criteria for co-morbidities were often described in general terms such as “adequate organ function” or “no major co-morbidities”, while others described minimum requirement for blood analyses (hematologic, liver and renal). The minimal required interval from previous RT was 6 months in two trials and 12 months in one trial. Six trials did not explicitly state a timeframe but described that a number of factors should be taken into account before inclusion such as “presence of severe side effect from previous treatment, time since primary therapy and response to primary therapy”. Endpoints and follow-up The primary endpoints were 1-year local control (n = 2), 3-year local control (n = 1), and a combination of 3-year locoregional control, progression-free and overall survival (n = 1). Two studies had R0 resection (resection margin >0 mm) as the primary endpoint and three were dose-escalation studies with maximum tolerated dose (MTD)/dose limiting toxicity (DLT) as the primary endpoint: two regarded radiation dose (hypofractionated proton therapy and endorectal HDR brachytherapy) and one MTD/DLT of TAS-102 in combination with RT or reirradiation. Secondary endpoints were broadly similar across studies and included local recurrence-free survival, colostomy-free survival, progression-free survival, overall survival, and response rates. Acute and late adverse events were included in all studies and patient reported outcomes in all but one, and surgical complications where applicable. Toxicity and PRO assessment Eight trials captured adverse effects using Common Terminology Criteria for Adverse Events (CTCAE), one also included Clavien–Dindo for surgical complications, and one used a toxicity system developed by the Intraoperative Radiation Therapy Working Group [21]. PRO instruments were used in seven trials; the EORTC questionnaires were most common, followed by EQ-5D-5L and LARS score. The planned follow-up ranged from 3 to 5 years for the majority of studies, but for the three MTD/DLT studies it was less, 1–2 years. The assessment of acute (baseline to 3 months) adverse effects and patient reported outcomes were generally done at baseline, weekly during reirradiation, and/or at end of RT, and after 3 months. Early late adverse events (3–12 months) were most commonly assessed in 3-month intervals with variation of 4 to 6 months. Late toxicity (>1 year) was most frequently assessed annually or every 6–12 months up to the end of follow-up. PROs were typically collected at baseline, end of RT, and at similar intervals to toxicity scoring, with decreasing frequency beyond the first year. Reirradiation dose and fractionation Reirradiation dose and fractionation were highly variable, as demonstrated in Table 2 with radiation doses from particle therapy trials given in relative biological effectiveness, (RBE). Hyperfractionated and accelerated regimens included doses from 40.8 in 34 fractions to 65 Gy(RBE) in 52 fractions (all twice daily). One study used 30 Gy in 15 fractions and one several schedules from conventional fractionation with 40–50 Gy in 1.8–2 Gy fractions to 40 Gy in 5 Gy fractions and 40–60 Gy(RBE) in 3–4.8 Gy fractions (carbon ions). One study used a moderately hypofractionated schedule with 30 Gy in 10 fractions, and one used hypofractionated regimens of 30–40 Gy in 5 Gy fractions. One study with endorectal brachytherapy used doses from 15 to 21 Gy given over 3 fractions. EQ.D2 corrected dose intervals for the nine trials are displayed in Fig. 1 with an α/β = 3 to represent late reacting normal tissue. In supplementary table 4 the exact values per trial can be seen.Fig. 1Reirradiation doses (dot) or dose range (connected dots) in each trial. Doses (> or < 1.8–2 Gy per fraction) are EQ.D2 corrected with an α/β = 3 to represent effects to late responding tissues. Abbreviations: EQ.D2: equivalent dose in 2 Gy fractions, Gy: Gray.Note: Trial 3 has 3 different schedules 3a-cFig. 1 Reirradiation doses (dot) or dose range (connected dots) in each trial. Doses (> or < 1.8–2 Gy per fraction) are EQ.D2 corrected with an α/β = 3 to represent effects to late responding tissues. Abbreviations: EQ.D2: equivalent dose in 2 Gy fractions, Gy: Gray. Note: Trial 3 has 3 different schedules 3a-c Radiotherapy techniques, preparation, and imaging Photon intensity modulated or volumetric modulated arc radiotherapy (IMRT/VMAT) was used in 5 trials, but in 3 of these trials other modalities were also allowed (including IORT, intensity modulated proton therapy (IMPT), carbon ion radiotherapy (CIRT), magnetic resonance imaging guided radiotherapy (MRIgRT) or 3D conformal therapy). Three studies were dedicated to proton therapy and one to high dose rate (HDR) brachytherapy. Patient preparation and positioning Most trials did not specify any required patient preparation. Some described patient preparation on an individual basis, and bladder filling was used in two trials. The brachytherapy trial used fiducial markers. Eight trials treated patients in the supine position, one also allowed for prone positioning, and one specified prone positioning only. Imaging for delineation and planning Eight trials used computed tomography (CT) for treatment planning; and also incorporated MRI, often both diagnostic (n = 5) and RT-specific (n = 5). One study used MRI only. Five studies used either diagnostic positron emission tomography (PET)-CT or PET-CT in treatment position. Eight studies stated that all available imaging was used for gross tumour volume (GTV) target definition, one study (brachytherapy) used MRI and fiducials. Further information from clinical examination and endoscopies was used if available. In most studies (n = 6), the GTV to CTV margin consisted of a 1 cm isotropic margin around the GTV, anatomically constrained. One study used a 2–5 mm margin, and one study reported “individual” margin expansions. For SBRT, the RETRY study reported no CTV margin was used. The CTV to PTV margin was 5–10 mm in five studies, and three studies used proton specific optimisation criteria. For brachytherapy neither CTV nor PTV margins were reported. For the SBRT study, a PTV margin of 3–5 mm was used. Organs of interest and constraints The following pelvic OOIs were routinely considered: bowel -either bowel bag or loops - were used by all except the brachytherapy study. Bladder was delineated by all, bone in six studies, rectum and anal canal in five and seven studies, respectively, four studies delineated nerves and penile structures, while one study used “genitalia” and three vaginal contours. Skin, ureter, urethra, vessels were each delineated in three studies. Reported dose objectives or optimization criteria used for OOIs were heterogeneous. Three trials reported as low as reasonably achievable (ALARA) or individual/patient specific constraints. Three trials reported using individual considerations guided by doses published by Abusaris et al. or Murray et al. [22], [23]. These studies report comparatively high cumulative dose limits for pelvic reirradiation, consistent with the relatively high reirradiation doses used in these three trials - up to 40 Gy in 8 Gy fractions, 60 Gy(RBE) in 4.8 Gy fractions and 65 Gy(RBE) in 1.25 Gy fractions. Reported dose guidance from the 3 remaining studies, using different treatment techniques, is summarized in Table 3 as well as guidance from Abusaris et al. The IMPARC study assumed that OOIs previously received 50 Gy from the prior RT treatment course and stressed that constraints were “soft”. This study included dose escalation from 30Gy in five fractions to 40 Gy in 5 fractions.Table 3OOI objectives as specified in three studies and Abusaris et al.OOIBrachytherapy StudyNCT0219923615 Gy in 5 Gy fractions – 21 Gy in 7 Gy fractionsEBRT StudyNCT03297710(30 Gy / 10 fractions)IMPARC Study NCT04827732 (30–40 Gy / 5 fractions)Abusaris et al.(1)RectumRectal surface Dmax <15 Gy/fractions–Rectum V50Gy < 3.5 ccRectum V110Gy <10 ccBladderDmax <5 Gy/fractionsV30Gy < 25%; Mean < 20 GyBladder wall V20Gy < 15 ccV120 Gy < 10 ccUrethraDmax <4 Gy/fx––Bowel (unspecified)Dmax <4 Gy/fractions––V110Gy < 10 ccSmall bowel–V33Gy < 0.1 cc; V30Gy < 10 ccV20Gy < 30 ccLarge bowel–V33Gy < 0.1 cc; V30Gy < 10 ccV28.5Gy < 20 ccFemoral head(s)–V33Gy < 0.1 cc; Mean < 20 GyV15Gy < 10 ccGenitalia–V33Gy < 0.1 cc; Mean < 20 Gy–Spinal cord––V10Gy < 0.35 ccCauda equina––V12Gy < 5 ccSacral plexus––V12Gy < 5 ccSkin––V22.5Gy < 10 ccUreter––D0.035cc < 30 GyPenile bulb––V15Gy < 3 ccAbbreviations: OOI: organs of interest, V: volume, D: dose, Gy: Gray, cc: cubic centimetres. Table 3OOI objectives as specified in three studies and Abusaris et al.OOIBrachytherapy StudyNCT0219923615 Gy in 5 Gy fractions – 21 Gy in 7 Gy fractionsEBRT StudyNCT03297710(30 Gy / 10 fractions)IMPARC Study NCT04827732 (30–40 Gy / 5 fractions)Abusaris et al.(1)RectumRectal surface Dmax <15 Gy/fractions–Rectum V50Gy < 3.5 ccRectum V110Gy <10 ccBladderDmax <5 Gy/fractionsV30Gy < 25%; Mean < 20 GyBladder wall V20Gy < 15 ccV120 Gy < 10 ccUrethraDmax <4 Gy/fx––Bowel (unspecified)Dmax <4 Gy/fractions––V110Gy < 10 ccSmall bowel–V33Gy < 0.1 cc; V30Gy < 10 ccV20Gy < 30 ccLarge bowel–V33Gy < 0.1 cc; V30Gy < 10 ccV28.5Gy < 20 ccFemoral head(s)–V33Gy < 0.1 cc; Mean < 20 GyV15Gy < 10 ccGenitalia–V33Gy < 0.1 cc; Mean < 20 Gy–Spinal cord––V10Gy < 0.35 ccCauda equina––V12Gy < 5 ccSacral plexus––V12Gy < 5 ccSkin––V22.5Gy < 10 ccUreter––D0.035cc < 30 GyPenile bulb––V15Gy < 3 ccAbbreviations: OOI: organs of interest, V: volume, D: dose, Gy: Gray, cc: cubic centimetres. OOI objectives as specified in three studies and Abusaris et al. Abbreviations: OOI: organs of interest, V: volume, D: dose, Gy: Gray, cc: cubic centimetres. Information on prior radiotherapy and cumulative dose evaluation For six trials, the minimum requirements for prior RT information were simple data, such as plan summary, dose metrics or at least dose and fractionation. Two studies had no minimal requirements and one required full information including 3D dose distribution in digital imaging and communications in medicine (DICOM). If imaging from previous RT was available, three studies used rigid image registration, and four studies described it as depending on individual factors. Evaluation of cumulative doses were undertaken by review of isodose overlay or point dose summation for four studies and, when available, five studies used 3D dose summation. Two studies did not specify or use dose accumulation. Six studies used summed EQ.D2/BED-corrected doses, one used physical dose, and two did not specify or use summed doses. None of the studies reported using a formal numerical tissue recovery factor. Four studies reported applied α/β values; all OOIs used an α/β of 3 in general, two used an α/β of 2 Gy for neural structures (e.g. spinal cord, sacral plexus). See summary in Supplementary Table 3. Recommendations Based on this survey, we developed and propose 12 pragmatic recommendations for future lower GI reirradiation trials. Together, these recommendations may help streamline trial conduct and improve the interpretability and comparability of results across studies, summarized in Table 4.Table 4Pragmatic recommendations to consider for future lower GI pelvic reirradiation trials.Pragmatic Recommendations for Future Lower GI Pelvic Reirradiation TrialsDomainPragmatic Recommendations for considerationElements to Report / ImplementTrial designState the clinical treatment intent at registration and predefine how changes to treatment intent are handledIntent: preoperative vs definitive vs palliativeReirradiation DefinitionUse standardised terminology for what constitutes reirradiationESTRO/EORTC reirradiation type [2]Prior Radiotherapy DocumentationRequire comprehensive prior RT data when feasibleRetrieve full DICOM-RT when availableConsensus on standard are described in detail:[3], [4]Cumulative Dose MethodologyPredefine cumulative dose evaluationRegistration and dose summation methods.Consensus on standard are described in detail:[3], [4]Planning & Delivery BasicsStandardize description of planning context so planning objective are interpretableImaging used (CT/MRI/PET, treatment-position vs diagnostic).Margins (GTV–CTV, CTV–PTV).Patient preparation, position, IGRT/adaptation strategyOOI SetConsider including a minimum pelvic reirradiation–relevant OOI panelDepends on OOI within reirradiation field: may include bowel*, bladder, femoral heads, rectum, anal canal, sacral plexus, cauda equina, skin, genital structuresDose ObjectivesReport both intended objectives and achieved doses for OOITable with dose objectives (hard/soft and/or relative prioritisation) and what was achieved in planningEndpoints by IntentAlign endpoints with preoperative vs definitive goalsPreoperative: R0, conversion to resectability, surgical morbidity, locoregional control.Definitive: locoregional control, symptoms or functional outcomesSystemic TherapyDefine how systemic therapy will be incorporated in the trialDetail on planned concurrent systemic therapy agentsReport use of induction or consolidation therapyAdverse EffectsUse uniform toxicity definitions and timepoints to enable poolingUse CTCAE; define acute e.g. < 3 months, late ≥3 months.Assess at relevant timepoints (e.g. baseline, end RT, 3/6/12/24/36 months)PROsInclude standard PROs routinelyCore instruments are EORTC questionnaires QOL-C30, CR29 and Anl27. Add e.g. bowel function scores and sexual function toolsAligned timepoints with clinician-reported toxicityAbbreviations: CT: computed tomography, CTCAE: common terminology criteria for adverse events, CTV: clinical target volume, EORTC: European Organisation For Research And Treatment Of Cancer, ESTRO: European Society for Radiotherapy and Oncology, GI: gastrointestinal, GTV: gross tumour volume, IGRT: image guided radiotherapy, MRI: magnetic resonance imaging, mos: months, OOI: organs of interest, PET: positron emisson tomography, PROs: patient reported outcomes, PTV: planning target volume, RO: margin negative resection, RT: radiotherapy.Note: *specify contouring method (e.g. bowel bag, bowel loops). Table 4Pragmatic recommendations to consider for future lower GI pelvic reirradiation trials.Pragmatic Recommendations for Future Lower GI Pelvic Reirradiation TrialsDomainPragmatic Recommendations for considerationElements to Report / ImplementTrial designState the clinical treatment intent at registration and predefine how changes to treatment intent are handledIntent: preoperative vs definitive vs palliativeReirradiation DefinitionUse standardised terminology for what constitutes reirradiationESTRO/EORTC reirradiation type [2]Prior Radiotherapy DocumentationRequire comprehensive prior RT data when feasibleRetrieve full DICOM-RT when availableConsensus on standard are described in detail:[3], [4]Cumulative Dose MethodologyPredefine cumulative dose evaluationRegistration and dose summation methods.Consensus on standard are described in detail:[3], [4]Planning & Delivery BasicsStandardize description of planning context so planning objective are interpretableImaging used (CT/MRI/PET, treatment-position vs diagnostic).Margins (GTV–CTV, CTV–PTV).Patient preparation, position, IGRT/adaptation strategyOOI SetConsider including a minimum pelvic reirradiation–relevant OOI panelDepends on OOI within reirradiation field: may include bowel*, bladder, femoral heads, rectum, anal canal, sacral plexus, cauda equina, skin, genital structuresDose ObjectivesReport both intended objectives and achieved doses for OOITable with dose objectives (hard/soft and/or relative prioritisation) and what was achieved in planningEndpoints by IntentAlign endpoints with preoperative vs definitive goalsPreoperative: R0, conversion to resectability, surgical morbidity, locoregional control.Definitive: locoregional control, symptoms or functional outcomesSystemic TherapyDefine how systemic therapy will be incorporated in the trialDetail on planned concurrent systemic therapy agentsReport use of induction or consolidation therapyAdverse EffectsUse uniform toxicity definitions and timepoints to enable poolingUse CTCAE; define acute e.g. < 3 months, late ≥3 months.Assess at relevant timepoints (e.g. baseline, end RT, 3/6/12/24/36 months)PROsInclude standard PROs routinelyCore instruments are EORTC questionnaires QOL-C30, CR29 and Anl27. Add e.g. bowel function scores and sexual function toolsAligned timepoints with clinician-reported toxicityAbbreviations: CT: computed tomography, CTCAE: common terminology criteria for adverse events, CTV: clinical target volume, EORTC: European Organisation For Research And Treatment Of Cancer, ESTRO: European Society for Radiotherapy and Oncology, GI: gastrointestinal, GTV: gross tumour volume, IGRT: image guided radiotherapy, MRI: magnetic resonance imaging, mos: months, OOI: organs of interest, PET: positron emisson tomography, PROs: patient reported outcomes, PTV: planning target volume, RO: margin negative resection, RT: radiotherapy.Note: *specify contouring method (e.g. bowel bag, bowel loops). Pragmatic recommendations to consider for future lower GI pelvic reirradiation trials. Abbreviations: CT: computed tomography, CTCAE: common terminology criteria for adverse events, CTV: clinical target volume, EORTC: European Organisation For Research And Treatment Of Cancer, ESTRO: European Society for Radiotherapy and Oncology, GI: gastrointestinal, GTV: gross tumour volume, IGRT: image guided radiotherapy, MRI: magnetic resonance imaging, mos: months, OOI: organs of interest, PET: positron emisson tomography, PROs: patient reported outcomes, PTV: planning target volume, RO: margin negative resection, RT: radiotherapy. Note: *specify contouring method (e.g. bowel bag, bowel loops). Discussion Pelvic reirradiation is increasingly used for LRRC and anal cancers to improve local control and, in selected patients, facilitate radical salvage surgery [4], [5], [24], [25]. However, practice remains heterogeneous due to limited prospective evidence and uncertainty around cumulative dose-toxicity relationships [14], [26]. Recent consensus efforts have emphasised the need for standardised definitions and reporting, and the new ESTRO guideline on the use, planning and delivery of reirradiation for rectal cancer highlights the need for high level evidence [7], [14], [15], [26], [27]. Given this, the ReCOG lower GI working group conducted a questionnaire-based survey of prospective pelvic reirradiation trials for rectal and anal cancer. We observed both convergence and marked heterogeneity in how reirradiation is defined, planned, and reported in this setting. Across included trials, all protocols employed conformal RT techniques, most frequently IMRT/VMAT, with additional use of protons, carbon ions, brachytherapy, and IORT. While this aligns with contemporary practice in reirradiation where conformality is central to limiting further dose to critical organs, the survey highlights that conformal delivery alone does not guarantee cross-trial interpretability. Planning choices and, critically, how prior dose is reconstructed and accumulated, remain variably specified and implemented. Furthermore, not all technical details were consistently captured, including elements such as IGRT strategy or adaptive workflows. Adopting standard reirradiation terminology using the ESTRO/EORTC framework [14] was feasible for all trials, with the majority representing type 1 reirradiation (overlap of treated volumes). However, the practical implications of a type 1 scenario, namely reliable cumulative dose estimation and transparent reporting of overlap and constraints, were not consistently operationalized. This gap matters because type 1 reirradiation is precisely the context in which uncertainty around dose accumulation, organ motion, and surgical/anatomical change most strongly affects both safety and the interpretability of dose-toxicity relationships. The heterogeneity in dose and fractionation observed in this survey is clinically understandable and not surprising, given the breadth of scenarios encompassed by lower GI pelvic reirradiation. A key lower GI-specific challenge is that the intent of reirradiation differs and includes both preoperative therapy to facilitate salvage surgery and as definitive therapy when surgery is not feasible or declined [4], [5]. These intents imply different risk-benefit thresholds and naturally drive different dose schemas, systemic therapy use, and follow-up strategies. Importantly, intent may also evolve during a patient's course (e.g., initially preoperative with later transition to definitive due to reassessment of resectability), which complicates endpoint specification and analysis unless protocols predefine how such transitions are handled. This intent heterogeneity also has direct implications for endpoint selection. In preoperative settings, endpoints such as R0 resection rate, conversion to resectability, surgical complication rates, and locoregional control after resection are central, and should be integrated with systematic reporting of perioperative morbidity. In definitive settings, durable local control, symptom control, colostomy-free survival, and long-term functional outcomes become even more important. Our survey suggests that future trials of lower GI reirradiation would benefit from explicitly stratifying or tailoring primary and secondary endpoints by intent, while maintaining a shared core of adverse effects and PRO assessments to enable comparisons. Due to significant variability in dose-fractionation and modality, approaches to OOI dose objectives and cumulative dose limits were also heterogeneous. Individualised constraints may be appropriate in specific circumstances - for example, when surgery is planned, when modalities with distinct dose distributions are used, or when prior dose data are incomplete or unavailable. However, individualised constraints and inconsistent cumulative dose methods reduce cross-trial comparability and hinder the development of generalisable dose-toxicity relationships. Compounding this, it is often unclear with what granularity of dosimetric data trials are collected and retained for later analyses. If the field aims to establish evidence-based cumulative dose-guidance tables, future studies will need to be more explicit about which comprehensive dosimetric data are captured, ideally including centrally stored full DICOM datasets (structures, plans, 3D dose distributions) and the imaging required for registration for relevant treatment courses [28], [29]. Without these data, subsequent pooled analyses will remain limited to approximations and will struggle to support robust constraint development. Heterogeneity across reirradiation studies may, however, also broaden exploration of dose-volume and outcome relationships across clinical scenarios and supporting future refinement of dose-toxicity relationships. Use of systemic therapy, which agent(s), and sequencing further amplify the heterogeneity in clinical scenarios. Most studies used concurrent capecitabine/5-fluorouracil, but induction, consolidation, and experimental systemic regimens varied across trials. These choices influence both outcomes and toxicity profiles and should be treated accordingly. Similarly, differences in surgical strategy (planned re-resection, timing of surgery post-reirradiation, and the use of IORT) create distinct composite treatments that require consistent reporting to interpret oncologic and toxicity outcomes. A consistent strength across trials was the emphasis on toxicity assessment, with most protocols using CTCAE and many incorporated PRO measures. Given the importance of functional outcomes in pelvic reirradiation, PRO integration should be viewed as essential rather than optional, and harmonisation of both instruments and timepoints would improve data synthesis. A pragmatic shared schedule would preserve trial autonomy while enabling pooled analyses of clinically meaningful late effects. An important limitation of this study is the potential for non-response bias, as only 9 of 21 eligible trials completed the questionnaire. Comparison of responding and non-responding studies based on publicly available registry data demonstrated variation in geographical location, disease site, trial phase, treatment modality, which may limit the generalizability of our findings. It is possible that studies with more mature protocols, greater methodological detail, or closer links to the ReCOG network were more likely to participate. Furthermore, three responding studies (ReRad I-III) originated from the same Scandinavian research environment, which may have increased methodological consistency among respondents and contributed to selection bias. Consequently, the similarities observed across studies should be interpreted with caution and may not fully reflect the diversity of ongoing lower gastrointestinal reirradiation trials worldwide. The proposed recommendations do not constitute formal consensus recommendations derived from a Delphi process or predefined voting framework and should be interpreted as pragmatic expert-opinion guidance informed by the survey findings rather than formal consensus statements. As most studies included patients with recurrent rectal cancer, the proposed recommendations are primarily informed by rectal cancer practice. Although several technical principles are applicable across lower gastrointestinal malignancies, disease-specific differences in histology, radiosensitivity, treatment strategies, and patterns of recurrence may limit the generalizability of some recommendations to anal cancer, highlighting the need for future disease-specific research. Conclusion Taken together, our survey demonstrates that while dose and fractionation across lower GI pelvic reirradiation trials for recurrent rectal and anal cancers will continue to differ because of differences in intent and modality, it is realistic to standardize definitions, minimum data capture, and outcome reporting. Doing so would allow different approaches (preoperative vs definitive, photons vs particles vs brachytherapy, various fractionation schemas) to contribute coherently to shared evidence generation, including future constraint refinement and decision-support tools, and, hopefully, ultimately improving outcomes. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work the author(s) used ChatGPT for language support and inconsistencies. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article CRediT authorship contribution statement Camilla Kronborg: Writing – review & editing, Writing – original draft, Visualization, Validation, Resources, Methodology, Formal analysis, Data curation, Conceptualization. Ane Appelt: Writing – review & editing, Visualization, Methodology, Formal analysis, Conceptualization. Pim Burger: Writing – review & editing, Validation, Investigation. Kyle Cuneo: Writing – review & editing, Methodology, Conceptualization. Aileen Duffton: Writing – review & editing, Methodology, Conceptualization. Maria Gambacorta: Writing – review & editing, Validation, Investigation. Marianne G. Guren: Writing – review & editing, Methodology, Conceptualization. Christopher Hallemeier: Writing – review & editing, Validation, Investigation. Allen Mo: Writing – review & editing, Validation, Investigation. Rebecca Muirhead: Writing – review & editing, Methodology, Conceptualization. Donna H. Murrell: Writing – review & editing, Methodology, Conceptualization. Dawn Owen: Writing – review & editing, Methodology, Conceptualization. Heike Peulen: Writing – review & editing, Methodology, Conceptualization. Heidi S. Rønde: Writing – review & editing, Methodology, Conceptualization. Karen-Lise G. Spindler: Writing – review & editing, Validation, Investigation. Jennifer Tan: Writing – review & editing, Validation, Investigation. Abraham J. Wu: Writing – review & editing, Validation, Investigation. Kilian E. Salerno: Writing – review & editing, Writing – original draft, Visualization, Methodology, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.